Regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing in cancer

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Siegfried, Zahava ^a   Bonomi, Serena ^b   Ghigna, Claudia ^b   Karni, Rotem ^a  

^a HEBREW UNIVERSITY   (Israel)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GUANOSINE TRIPHOSPHATASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPYRIMIDINE TRACT BINDING PROTEIN; PROTEIN S6; PYRUVATE KINASE; PYRUVATE KINASE M; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; COLORECTAL CANCER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; EXON; GENE REARRANGEMENT; HEAD AND NECK CARCINOMA; LUNG SMALL CELL CANCER; NEOPLASM; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION;

EID: 84885343036     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/568931     Document Type: Review

References (91)

1. Bonnal S., Vigevani L., Valcarcel J., The spliceosome as a target of novel antitumour drugs. Nature Reviews Drug Discovery 2012 11 11 847 859
2. Warzecha C. C., Carstens R. P., Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Seminars in Cancer Biology 2012 22 5-6 417 427 2-s2.0-84860594334 10.1016/j.semcancer.2012.04.003
3. Kim E., Goren A., Ast G., Insights into the connection between cancer and alternative splicing. Trends in Genetics 2008 24 1 7 10 2-s2.0-37349089805 10.1016/j.tig.2007.10.001 (Pubitemid 350298628)
4. Singh R. K., Cooper T. A., Pre-mRNA splicing in disease and therapeutics. Trends in Molecular Medicine 2012 18 8 472 482
5. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., Pellagatti A., Wainscoat J. S., Hellstrom-Lindberg E., Gambacorti-Passerini C., Godfrey A. L., Rapado I., Cvejic A., Rance R., McGee C., Ellis P., Mudie L. J., Stephens P. J., McLaren S., Massie C. E., Tarpey P. S., Varela I., Nik-Zainal S., Davies H. R., Shlien A., Jones D., Raine K., Hinton J., Butler A. P., Teague J. W., Baxter E. J., Score J., Galli A., Della Porta M. G., Travaglino E., Groves M., Tauro S., Munshi N. C., Anderson K. C., El-Naggar A., Fischer A., Mustonen V., Warren A. J., Cross N. C. P., Green A. R., Futreal P. A., Stratton M. R., Campbell P. J., Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New England Journal of Medicine 2011 365 15 1384 1395 2-s2.0-80054010617 10.1056/NEJMoa1103283
6. Harbour J. W., Roberson E. D. O., Anbunathan H., Onken M. D., Worley L. A., Bowcock A. M., Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nature Genetics 2013 45 2 133 135
7. Quesada V., Ramsay A. J., Lopez-Otin C., Chronic lymphocytic leukemia with SF3B1 mutation. New England Journal of Medicine 2012 366 26 2530
8. Quesada V., Conde L., Villamor N., Ordóñez G. R., Jares P., Bassaganyas L., Ramsay A. J., Beà S., Pinyol M., Martínez-Trillos A., López-Guerra M., Colomer D., Navarro A., Baumann T., Aymerich M., Rozman M., Delgado J., Giné E., Hernández J. M., González-Díaz M., Puente D. A., Velasco G., Freije J. M. P., Tubío J. M. C., Royo R., Gelpí J. L., Orozco M., Pisano D. G., Zamora J., Vázquez M., Valencia A., Himmelbauer H., Bayés M., Heath S., Gut M., Gut I., Estivill X., López-Guillermo A., Puente X. S., Campo E., López-Otín C., Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics 2012 44 1 47 52 2-s2.0-84555171449 10.1038/ng.1032
9. Cohen-Eliav M., Golan-Gerstl R., Siegfried Z., The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. The Journal of Pathology 2013 229 4 630 639 10.1002/path.4129
10. Venables J. P., Unbalanced alternative splicing and its significance in cancer. BioEssays 2006 28 4 378 386 2-s2.0-33645833000 10.1002/bies.20390
11. Venables J. P., Klinck R., Koh C., Cancer-associated regulation of alternative splicing. Nature Structural & Molecular Biology 2009 16 6 670 676 10.1038/nsmb.1608
12. Jia R., Li C., McCoy J. P., Deng C.-X., Zheng Z.-M., SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. International Journal of Biological Sciences 2010 6 7 806 826 2-s2.0-78650553169
13. Lefave C. V., Squatrito M., Vorlova S., Rocco G. L., Brennan C. W., Holland E. C., Pan Y.-X., Cartegni L., Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO Journal 2011 30 19 4084 4097 2-s2.0-80053577349 10.1038/emboj.2011.259
14. Karni R., De Stanchina E., Lowe S. W., Sinha R., Mu D., Krainer A. R., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology 2007 14 3 185 193 2-s2.0-33847630730 10.1038/nsmb1209 (Pubitemid 46355578)
15. Golan-Gerstl R., Cohen M., Shilo A., Suh S.-S., Bakàcs A., Coppola L., Karni R., Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Research 2011 71 13 4464 4472 2-s2.0-79959892321 10.1158/0008-5472.CAN-10-4410
16. Yuan T. L., Cantley L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008 27 41 5497 5510 2-s2.0-51849111556 10.1038/onc.2008.245
17. Shaw R. J., Cantley L. C., Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006 441 7092 424 430 2-s2.0-33745307617 10.1038/nature04869 (Pubitemid 44050136)
18. Laplante M., Sabatini D. M., MTOR signaling in growth control and disease. Cell 2012 149 2 274 293 2-s2.0-84859778293 10.1016/j.cell.2012.03.017
19. Druillennec S., Dorard C., Eychene A., Alternative splicing in oncogenic kinases: from physiological functions to cancer. Journal of Nucleic Acids 2012 2012 14 639062 10.1155/2012/639062
20. Baitei E. Y., Zou M., Al-Mohanna F., Collison K., Alzahrani A. S., Farid N. R., Meyer B., Shi Y., Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. Journal of Pathology 2009 217 5 707 715 2-s2.0-64549083309 10.1002/path.2496
21. Poulikakos P. I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M. T., Salton M., Dahlman K. B., Tadi M., Wargo J. A., Flaherty K. T., Kelley M. C., Misteli T., Chapman P. B., Sosman J. A., Graeber T. G., Ribas A., Lo R. S., Rosen N., Solit D. B., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011 480 7377 387 390 2-s2.0-83455254767 10.1038/nature10662
22. Heakal Y., Kester M., Savage S., Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Annals of Pharmacotherapy 2011 45 11 1399 1405 2-s2.0-80155161402 10.1345/aph.1Q363
23. Barnett C. M., Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy 2012 32 4 383 396
24. Kim K. B., Kefford R., Pavlick A. C., Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of Clinical Oncology 2013 31 4 482 489 10.1200/JCO.2012.43.5966
25. Flaherty K. T., Infante J. R., Daud A., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine 2012 367 18 1694 1703
26. Patel S. P., Lazar A. J., Papadopoulos N. E., Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 2013 119 4 799 805 10.1002/cncr.27790
27. Pedersen M. W., Tkach V., Pedersen N., Berezin V., Poulsen H. S., Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. International Journal of Cancer 2004 108 5 643 653 2-s2.0-0347285400 10.1002/ijc.11566 (Pubitemid 38076395)
28. Vorlová S., Rocco G., LeFave C. V., Jodelka F. M., Hess K., Hastings M. L., Henke E., Cartegni L., Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Molecular Cell 2011 43 6 927 939 2-s2.0-80052999677 10.1016/j.molcel.2011.08.009
29. Warzecha C. C., Sato T. K., Nabet B., Hogenesch J. B., Carstens R. P., ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Molecular Cell 2009 33 5 591 601 2-s2.0-61649087689 10.1016/j.molcel.2009.01.025
30. Ho T. H., Savkur R. S., Poulos M. G., Mancini M. A., Swanson M. S., Cooper T. A., Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. Journal of Cell Science 2005 118 13 2923 2933 2-s2.0-23744450059 10.1242/jcs.02404 (Pubitemid 41136369)
31. Savkur R. S., Philips A. V., Cooper T. A., Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature Genetics 2001 29 1 40 47 2-s2.0-0034873099 10.1038/ng704 (Pubitemid 32801806)
32. Mezquita B., Mezquita J., Pau M., Mezquita C., A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells. Journal of Cellular Biochemistry 2010 110 3 732 742 2-s2.0-77952688535 10.1002/jcb.22584
33. Thomas C. P., Raikwar N. S., Kelley E. A., Liu K. Z., Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation. Nucleic Acids Research 2010 38 15 5130 5140 2-s2.0-77956096765 10.1093/nar/gkq198 gkq198
34. Ghigna C., De Toledo M., Bonomi S., Valacca C., Gallo S., Apicella M., Eperon I., Tazi J., Biamonti G., Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biology 2010 7 4 495 503 2-s2.0-77957302252 10.4161/rna.7.4.12744
35. Ghigna C., Giordano S., Shen H., Benvenuto F., Castiglioni F., Comoglio P. M., Green M. R., Riva S., Biamonti G., Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Molecular Cell 2005 20 6 881 890 2-s2.0-29144447982 10.1016/j.molcel.2005.10.026 (Pubitemid 41814877)
36. Zhang P., Greendorfer J. S., Jiao J., Kelpke S. C., Thompson J. A., Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES. Archives of Biochemistry and Biophysics 2006 450 1 50 62 2-s2.0-33646861363 10.1016/j.abb.2006.03.017 (Pubitemid 43782732)
37. Chettouh H., Fartoux L., Aoudjehane L., Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Research 2013 73 13 3974 3986 10.1158/0008-5472.CAN-12-3824
38. Lee J.-H., Chong F. G., Chong C. L., Myung D. K., Woude G. F. V., An alternatively spliced form of Met receptor is tumorigenic. Experimental and Molecular Medicine 2006 38 5 565 573 2-s2.0-33750712731 (Pubitemid 44704055)
39. Tiran Z., Oren A., Hermesh C., Rotman G., Levine Z., Amitai H., Handelsman T., Beiman M., Chen A., Landesman-Milo D., Dassa L., Peres Y., Koifman C., Glezer S., Vidal-Finkelstein R., Bahat K., Pergam T., Israel C., Horev J., Tsarfaty I., Ayalon-Soffer M., A novel recombinant soluble splice variant of met is a potent antagonist of the hepatocyte growth factor/scatter factor-met pathway. Clinical Cancer Research 2008 14 14 4612 4621 2-s2.0-51649111766 10.1158/1078-0432.CCR-08-0108
40. Hirschi B., Kolligs F. T., Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. International Journal of Cancer 2013 133 3 590 596
41. Yang X., Guo Z., Sun F., Li W., Alfano A., Shimelis H., Chen M., Brodie A. M. H., Chen H., Xiao Z., Veenstra T. D., Qiu Y., Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. Journal of Biological Chemistry 2011 286 41 36152 36160 2-s2.0-80053923164 10.1074/jbc.M111.265124
42. Camats M., Kokolo M., Heesom K. J., Ladomery M., Bach-Elias M., P19 H-ras induces G1/S phase delay maintaining cells in a reversible quiescence state. PLoS ONE 2009 4 12 2-s2.0-77949512738 10.1371/journal.pone.0008513 e8513
43. Brignatz C., Paronetto M. P., Opi S., Cappellari M., Audebert S., Feuillet V., Bismuth G., Roche S., Arold S. T., Sette C., Collette Y., Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Molecular and Cellular Biology 2009 29 24 6438 6448 2-s2.0-71949096690 10.1128/MCB.00398-09
44. Guil S., De La Iglesia N., Fernández-Larrea J., Cifuentes D., Ferrer J. C., Guinovart J. J., Bach-Elias M., Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Research 2003 63 17 5178 5187 2-s2.0-0141705477 (Pubitemid 37139824)
45. Yokoyama T., Takano K., Yoshida A., Katada F., Sun P., Takenawa T., Andoh T., Endo T., DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. Journal of Cell Biology 2007 177 5 781 793 2-s2.0-34249880794 10.1083/jcb.200703195 (Pubitemid 46873085)
46. Rauch J., Moran-Jones K., Albrecht V., Schwarzl T., Hunter K., Gires O., Kolch W., c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Research 2011 71 13 4664 4674 2-s2.0-79959863480 10.1158/0008-5472.CAN-10-4447
47. Rowinsky E. K., The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annual Review of Medicine 2004 55 433 457 2-s2.0-1542329005 10.1146/annurev.med.55.091902.104433 (Pubitemid 38316736)
48. Sugawa N., Ekstrand A. J., James C. D., Collins V. P., Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proceedings of the National Academy of Sciences of the United States of America 1990 87 21 8602 8606 2-s2.0-0025114687
49. Nishikawa R., Ji X.-D., Harmon R. C., Lazar C. S., Gill G. N., Cavenee W. K., Huang H.-J. S., A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America 1994 91 16 7727 7731 2-s2.0-0028146767 10.1073/pnas.91.16.7727 (Pubitemid 24238258)
50. Weidle U. H., Maisel D., Klostermann S., Weiss E. H., Schmitt M., Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics and Proteomics 2011 8 5 211 226 2-s2.0-80054678708
51. Wang H., Zhou M., Shi B., Zhang Q., Jiang H., Sun Y., Liu J., Zhou K., Yao M., Gu J., Yang S., Mao Y., Li Z., Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011 13 5 461 471 2-s2.0-79955865397 10.1593/neo.101744
52. Yang W., Xia Y., Cao Y., EGFR-induced and PKCepsilon monoubiquitylation- dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Molecular Cell 2012 48 5 771 784 10.1016/j.molcel.2012.09.028
53. Clower C. V., Chatterjee D., Wang Z., Cantley L. C., Heidena M. G. V., Krainer A. R., The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proceedings of the National Academy of Sciences of the United States of America 2010 107 5 1894 1899 2-s2.0-76649102764 10.1073/pnas.0914845107
54. David C. J., Chen M., Assanah M., Canoll P., Manley J. L., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010 463 7279 364 368 2-s2.0-75149150660 10.1038/nature08697
55. Yang W., Zheng Y., Xia Y., ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biology 2012 14 12 1295 1304
56. Reiter J. L., Threadgill D. W., Eley G. D., Strunk K. E., Danielsen A. J., Schehl Sinclair C., Pearsall R. S., Green P. J., Yee D., Lampland A. L., Balasubramaniam S., Crossley T. D., Magnuson T. R., James C. D., Maihle N. J., Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001 71 1 1 20 2-s2.0-0035145809 10.1006/geno.2000.6341 (Pubitemid 32097198)
57. Baron A. T., Wilken J. A., Haggstrom D. E., Goodrich S. T., Maihle N. J., Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs 2009 12 5 302 308 2-s2.0-67649371211
58. Maramotti S., Paci M., Miccichè F., Ciarrocchi A., Cavazza A., De Bortoli M., Vaghi E., Formisano D., Canovi L., Sgarbi G., Bongarzone I., Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer 2012 76 3 332 338 2-s2.0-84860507315 10.1016/j.lungcan.2011.11.018
59. Halle C., Lando M., Svendsrud D. H., Clancy T., Holden M., Sundfør K., Kristensen G. B., Holm R., Lyng H., Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer. Clinical Cancer Research 2011 17 16 5501 5512 2-s2.0-80051685783 10.1158/1078-0432.CCR-11-0297
60. Philippou A., Armakolas A., Koutsilieris M., Evidence for the possible biological significance of the igf-1 gene alternative splicing in prostate cancer. Frontiers in Endocrinology 2013 4, article 31
61. Chen G., Wang J., Liu Z., Kornmann M., Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. Pancreas 2008 37 2 159 164 2-s2.0-55949100561 10.1097/MPA.0b013e31816618a4
62. Condorelli G., Bueno R., Smith R. J., Two alternatively spliced forms of the human insulin-like growth factor I receptor have distinct biological activities and internalization kinetics. Journal of Biological Chemistry 1994 269 11 8510 8516 2-s2.0-0028244050 (Pubitemid 24200276)
63. Marchini C., Gabrielli F., Iezzi M., Zenobi S., Montani M., Pietrella L., Kalogris C., Rossini A., Ciravolo V., Castagnoli L., Tagliabue E., Pupa S. M., Musiani P., Monaci P., Menard S., Amici A., The human splice variant δ 16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS ONE 2011 6 4 2-s2.0-79955712254 10.1371/journal.pone.0018727 e18727
64. Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., Elenius K., Function of ERBB4 is determined by alternative splicing. Cell Cycle 2011 10 16 2647 2657 2-s2.0-80051764374 10.4161/cc.10.16.17194
65. Sundvall M., Veikkolainen V., Kurppa K., Salah Z., Tvorogov D., Van Zoelen E. J., Aqeilan R., Elenius K., Cell death or survival promoted by alternative isoforms of ErbB4. Molecular Biology of the Cell 2010 21 23 4275 4286 2-s2.0-78650132637 10.1091/mbc.E10-04-0332
66. Aebersold D. M., Shaul Y. D., Yung Y., Yarom N., Yao Z., Hanoch T., Seger R., Extracellular Signal-Regulated Kinase 1c (ERK1c), a novel 42-kilodalton ERK, demonstrates unique modes of regulation, localization, and function. Molecular and Cellular Biology 2004 24 22 10000 10015 2-s2.0-7644222270 10.1128/MCB.24.22.10000-10015.2004 (Pubitemid 39458824)
67. Shaul Y. D., Gibor G., Plotnikov A., Seger R., Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade. Genes and Development 2009 23 15 1779 1790 2-s2.0-68149132138 10.1101/gad.523909
68. Adesso L., Calabretta S., Barbagallo F., Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013 32 23 2848 2857 10.1038/onc.2012.306
69. Fransson S., Uv A., Eriksson H., p37delta is a new isoform of PI3K p110delta that increases cell proliferation and is overexpressed in tumors. Oncogene 2012 31 27 3277 3286 10.1038/onc.2011.492
70. Lefai E., Roques M., Vega N., Laville M., Vidal H., Expression of the splice variants of the p85 α regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients. Biochemical Journal 2001 360 1 117 125 2-s2.0-0035890960 10.1042/0264-6021:3600117 (Pubitemid 33081955)
71. Agrawal S., Eng C., Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Human Molecular Genetics 2006 15 5 777 787 2-s2.0-33144470077 10.1093/hmg/ddi492 (Pubitemid 43264702)
72. Hoogeveen-Westerveld M., Ekong R., Povey S., Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. Human Mutation 2013 34 1 167 175 10.1002/humu.22202
73. Mayer K., Ballhausen W., Leistner W., Rott H.-D., Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochimica et Biophysica Acta 2000 1502 3 495 507 2-s2.0-0034670066 10.1016/S0925-4439(00)00072-7
74. Xu L., Sterner C., Maheshwar M. M., Wilson P. J., Nellist M., Short P. M., Haines J. L., Sampson J. R., Ramesh V., Alternative splicing of the tuberous sclerosis 2 (TSC2) gene in human and mouse tissues. Genomics 1995 27 3 475 480 2-s2.0-0029124823 10.1006/geno.1995.1079
75. Panasyuk G., Nemazanyy I., Zhyvoloup A., Filonenko V., Davies D., Robson M., Pedley R. B., Waterfield M., Gout I., mTOR β splicing isoform promotes cell proliferation and tumorigenesis. Journal of Biological Chemistry 2009 284 45 30807 30814 2-s2.0-70350544118 10.1074/jbc.M109.056085
76. Huot M.-É., Vogel G., Zabarauskas A., Ngo C. T.-A., Coulombe-Huntington J., Majewski J., Richard S., The Sam68 STAR RNA-binding protein regulates mTOR alternative splicing during adipogenesis. Molecular Cell 2012 46 2 187 199 2-s2.0-84860339073 10.1016/j.molcel.2012.02.007
77. Michlewski G., Sanford J. R., Cáceres J. F., The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Molecular Cell 2008 30 2 179 189 2-s2.0-42949109848 10.1016/j.molcel.2008.03. 013 (Pubitemid 351626689)
78. Ben-Hur V., Denichenko P., Siegfried Z., S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Reports 2013 3 1 103 115 10.1016/j.celrep.2012.11.020
79. Lynch K. W., Regulation of alternative splicing by signal transduction pathways. Advances in Experimental Medicine and Biology 2007 623 161 174 2-s2.0-42449123286
80. Stamm S., Regulation of alternative splicing by reversible protein phosphorylation. Journal of Biological Chemistry 2008 283 3 1223 1227 2-s2.0-38349085591 10.1074/jbc.R700034200
81. McCubrey J. A., Steelman L. S., Chappell W. H., Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 3 10 1068 1111
82. White E. S., Sagana R. L., Booth A. J., Yan M., Cornett A. M., Bloomheart C. A., Tsui J. L., Wilke C. A., Moore B. B., Ritzenthaler J. D., Roman J., Muro A. F., Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Experimental Cell Research 2010 316 16 2644 2653 2-s2.0-77955843468 10.1016/j.yexcr.2010.06.028
83. Shultz J. C., Goehe R. W., Wijesinghe D. S., Murudkar C., Hawkins A. J., Shay J. W., Minna J. D., Chalfant C. E., Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Research 2010 70 22 9185 9196 2-s2.0-78549234102 10.1158/0008-5472.CAN-10-1545
84. Patel N. A., Kaneko S., Apostolatos H. S., Sun S. B., Watson J. E., Davidowitz K., Chappell D. S., Birnbaum M. J., Cheng J. Q., Cooper D. R., Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase C β II alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. Journal of Biological Chemistry 2005 280 14 14302 14309 2-s2.0-20244372405 10.1074/jbc.M411485200 (Pubitemid 40517333)
85. Al-Ayoubi A. M., Zheng H., Liu Y., Bai T., Eblen S. T., Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Molecular and Cellular Biology 2012 32 14 2880 2893 10.1128/MCB.06327-11
86. Zhou Z., Qiu J., Liu W., The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Molecular Cell 2012 47 3 422 433 10.1016/j.molcel.2012.05.014
87. Allemand E., Guil S., Myers M., Moscat J., Cáceres J. F., Krainer A. R., Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proceedings of the National Academy of Sciences of the United States of America 2005 102 10 3605 3610 2-s2.0-14844367002 10.1073/pnas.0409889102 (Pubitemid 40354658)
88. Van Oordt W. V. D. H., Diaz-Meco M. T., Lozano J., Krainer A. R., Moscat J., Cáceres J. F., The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. Journal of Cell Biology 2000 149 2 307 316 2-s2.0-0007570010 10.1083/jcb.149.2.307 (Pubitemid 30227149)
89. Guil S., Long J. C., Cáceres J. F., hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Molecular and Cellular Biology 2006 26 15 5744 5758 2-s2.0-33746516731 10.1128/MCB.00224-06 (Pubitemid 44134331)
90. Karni R., Hippo Y., Lowe S. W., Krainer A. R., The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proceedings of the National Academy of Sciences of the United States of America 2008 105 40 15323 15327 2-s2.0-55749096250 10.1073/pnas.0801376105
91. Blaustein M., Pelisch F., Tanos T., Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nature Structural & Molecular Biology 2005 12 12 1037 1044 10.1038/nsmb1020 (Pubitemid 41746773)